Strategy for PDR

Protocol S demonstrates efficacy, but more information needed

Strategy for PDR
Cheryl Guttman Krader
Cheryl Guttman Krader
Published: Thursday, September 1, 2016
The Diabetic Retinopathy Clinical Research Network, Protocol S established intravitreal injection with ranibizumab 0.5mg (Lucentis, Novartis) as a new strategy for the management of proliferative diabetic retinopathy (PDR). However, application of the study results to clinical practice is challenging because there are many questions about pharmacotherapy for panretinal photocoagulation (PRP) that need to be answered, said Francisco J Rodriguez MD at WOC 2016 in Guadalajara, Mexico. “Ranibizumab will allow us to avoid complications of PRP, which include peripheral visual field loss, decreased visual acuity (VA), the development or worsening of diabetic macular oedema (DME), and severe visual loss in up to 10 per cent of patients. However, treatment selection for individual patients is influenced by a number of parameters, including long-term efficacy, predictors of response, potential side effects, convenience for the patient, the family and the physician, and most importantly cost, which introduces the payer as another player,” noted Dr Rodriguez, Scientific Director, Fundación Oftalmológica Nacional, and Chairman of the Department of Ophthalmology, Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, in Bogota, Colombia. “More time is needed to answer questions about the chronic use of anti-vascular endothelial growth factor (anti-VEGF) therapy for PDR and to determine what is the best long-term strategy. Perhaps it will be a combination of laser and pharmacotherapy,” he added. EMERGING DATA Protocol S was undertaken as emerging data from DME clinical trials showed that anti-VEGF treatment modulated the progression of DR. The study randomised 305 patients to prompt PRP completed at one to three sittings within eight weeks, or ranibizumab 0.5mg with four mandatory injections and continued as frequently as every four weeks. The primary outcome analysis of mean change in VA at two years showed ranibizumab was non-inferior to PRP. However, ranibizumab treatment offered some advantages. Compared with the PRP group, eyes assigned to the anti-VEGF injection group had superior mean VA over two years, better visual fields, decreased chance of vitrectomy, and less frequent development of DME. “We also know PRP has some advantages. Compared with anti-VEGF therapy, it is less expensive and carries no risks of endophthalmitis or systemic VEGF inhibition. Furthermore, the treatment typically is completed in just one or two visits, and it is often long-lasting,” Dr Rodriguez said. Looking ahead, Dr Rodriguez outlined several issues that need to be addressed for better guidance on the use of anti-VEGF therapy for PDR. “We need to know if the same outcomes are achieved when treating PDR with an 0.3mg dose of ranibizumab or other anti-VEGF agents,” he said. Francisco J Rodriguez: fjrodriguez@fon.org.co
Tags: proliferative diabetic retinopathy
Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...